医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

TLGY Acquisition Corporation Files 2021 Annual Report on Form 10-K

2022年04月01日 AM06:08
このエントリーをはてなブックマークに追加


 

NEW YORK

TLGY Acquisition Corporation (NASDAQ: TLGYU, TLGY and TLGYW) (the “Company” or “TLGY”), a blank check company formed as a Cayman Islands exempted company, announced today that it filed its annual report on Form 10-K for the fiscal year ended December 31, 2021 with the Securities and Exchange Commission (the “SEC”).

The annual report on Form 10-K, which contains the Company’s audited financial statements, can be accessed on the SEC’s website at www.sec.gov as well as through the Company’s website at www.tlgyacquisition.com.

The Company will provide a hard copy of its annual report containing the audited financial statements, free of charge, to its shareholders upon request. Requests should be directed to mail@tlgyacquisition.com.

About TLGY Acquisition Corporation

The Company is a blank check company sponsored by TLGY Sponsors LLC, whose business purpose is to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The Company intends to focus its search for an initial business combination on a promising global company—or a company with Asia linkages with the potential to become a global company—with a focus on biopharma or consumer businesses driven by enabling technology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220331006026/en/

CONTACT

Jin-Goon Kim

Founder and Chief Executive Officer

c/o TLGY Sponsors LLC

+852 9731 0995

mail@tlgyacquisition.com

www.tlgyacquisition.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Xlear Files Amended Answer to the Government’s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear’s Use as Additional Layer of Protection
  • EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
  • BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
  • ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
  • Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen